Vizient Medical Device Tech Watch presents trends in transcatheter valve replacement and a model for evaluating new technologies in musculoskeletal care


IRVING, Texas–(BUSINESS WIRE)–In his latest Medical Device Tech Watch, Vizient, Inc. provides updated trends in patient quality outcomes for transcatheter valve replacement, including information on complications and physician expertise. Additionally, this issue presents a technology adoption model to assess the clinical and financial impact of various technologies in musculoskeletal care. The full report is available here.

“While data and automation play a central role in how we as an industry can advance healthcare, our goal is to go further,” said Erik Axter, Chief Executive Officer. of Vizient, physician and clinical performance. “We strive to connect these data points, leading to informed decision-making and lasting performance improvements in critical service lines such as cardiology, orthopedics and neuroscience. Tech Watch continues to be a valuable channel for sharing this information with our members.

Featured items include:

Updated trend data shows impact on quality of transcatheter aortic valve implantation—Transcatheter aortic valve replacement (TAVR) has grown rapidly, benefiting patients who are not eligible or unwilling to undergo surgical valve replacement. Vizient compared industry results that look at case volume and mortality prior to 2018 to recent results from Vizient’s clinical database and found that while expected length of stay has increased, mortality rates decreased. The report also tracks the rate of complications and mortality by region as well as the relationship between clinician expertise in TAVI and better outcomes.

Model for evaluating new technologies in musculoskeletal care—As new devices and products come to market, Vizient has developed an adoption model to assess the clinical benefits and financial impact of musculoskeletal technologies. In a review that included Vizient Procedural Analytics data from 79 facilities over a six-month period, researchers applied the model to 3D-printed interbody spacers showing cost considerations for basic, advanced, and 3D-printed spacers. The report offers comprehensive guidelines for individual provider assessments.

Increase in Growth Predicted for the Intravascular Ultrasound Market—Coronary artery disease (CAD) is the most common type of heart disease in the United States, affecting approximately 18.2 million adults. Early detection and intervention remain key goals for health care providers. With new and evolving diagnostic tools and medical imaging techniques improving patient outcomes and care, this article provides an overview of intravascular ultrasound technology and other modalities, as a diagnostic tool and adjunct to angiography.

Back issues of Vizient Medical Device Tech Watch are available here.

About Vizient, Inc.

Vizient, Inc.., the nation’s largest healthcare performance improvement company, serves more than 50% of the nation’s acute care providers, which includes 97% of the nation’s academic medical centers and more than 20% of outpatient care. Vizient provides expertise, analysis and consulting services, as well as a contract portfolio that represents more than $130 billion in annual purchase volume. Vizient’s solutions and services improve the delivery of high-value care by aligning cost, quality, and market performance. Based in Irving, Texas, Vizient has offices across the United States. Learn more about


About Author

Comments are closed.